Assertio to be Acquired by Garda Therapeutics for $18/Share Cash Plus CVR; Divests Non-Rolvedon Assets to Cosette for $35M Upfront

summarizeSummary

Assertio Holdings, Inc. announced a definitive agreement to be acquired by Garda Therapeutics for $18.00 per share in cash plus a Contingent Value Right, following a strategic review and concurrent divestiture of non-Rolvedon assets to Cosette Pharmaceuticals for $35 million upfront plus earnouts.

check_boxKey Events

• Definitive Acquisition Agreement

  Assertio will be acquired by Garda Therapeutics for $18.00 per share in cash, plus a Contingent Value Right (CVR) for potential future milestones related to the Sprix product. This finalizes terms and pricing of the offering initiated on 2026-04-08.

• Significant Acquisition Premium

  The $18.00 per share cash offer represents a 34.6% premium to the company's unaffected stock price on March 20, 2026, providing a clear path to value for shareholders.

• Concurrent Asset Divestiture

  Assertio sold its non-Rolvedon product franchises (including Indocin, Sympazan, Sprix, Cambia, Zipsor, and Otrexup) to Cosette Pharmaceuticals for an upfront payment of $35 million, plus additional earnouts. Only Sprix-related earnouts are tied to the CVRs for Assertio shareholders.

• Acquisition Financing Secured

  Garda Therapeutics has secured $17 million in equity financing and $87 million in debt financing to fund the acquisition, demonstrating commitment to the transaction.

auto_awesomeAnalysis

This 8-K filing confirms the definitive terms of Assertio Holdings' acquisition by Garda Therapeutics, a highly material event for shareholders. The $18.00 per share cash offer, coupled with a Contingent Value Right, provides a substantial premium over the company's unaffected stock price, offering a clear path to value realization. The concurrent divestiture of non-Rolvedon assets to Cosette Pharmaceuticals for $35 million upfront plus earnouts streamlines Assertio's operations and contributes to the overall transaction structure. The secured financing and the "window-shop" period are important details that provide confidence in the deal's completion while also allowing for potential superior offers. Investors should monitor the tender offer process and any developments during the "window-shop" period.